Guru P. Sonpavde: Honored to write this commentary…

Guru P. Sonpavde, GU Oncology Director at Advent Health Cancer Institute, shared on X/Twitter:

“Nivolumab Plus Gemcitabine–Cisplatin as first-line therapy for Advanced Urothelial Carcinoma bladder cancer – honored to write this commentary – what is the role of Gem-Cis-Nivo in the context of EV-pembro and the platinum combination followed by maintenance Avelumab paradigms?”

For the article click here.
Source: Guru P. Sonpavde/Twitter